---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-090875"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:54:10.231569+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics Q2 net loss $13.4M; DKN-01 CRC trial advances to Part B

## Summary
- Net loss $13.4M in Q2 2023 vs $17.0M in Q2 2022; R&D expenses fell to $11.1M.
- Cash and equivalents $91.4M at June 30, 2023; interest income $1.2M.
- DeFianCe Part A CRC study achieved >20% ORR; 130-patient randomized Part B initiated.
- DisTinGuish GEA data: 73% ORR (mITT), median OS 19.5 months, median PFS 11.3 months.

## SEC filing metadata
- accession: 0001104659-23-090875
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465923090875/0001104659-23-090875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465923090875/tm2323558d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-090875
- JSON: https://secwatch.observer/filing/0001104659-23-090875.json
- Plain text: https://secwatch.observer/filing/0001104659-23-090875.txt

## Key facts
- Earnings Releases
  CYPHERPUNK TECHNOLOGIES INC. reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 14, 2023, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509745/000110465923090875/0001104659-23-090875-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.